GLYCOUNIVERSE GMBH & CO. KOMMANDITGESELLSCHAFT AUF AKTIEN

Their core work

GlycoUniverse is a Potsdam-based SME specializing in the production and supply of complex carbohydrates (glycans) and glycomimetic compounds for research and pharmaceutical applications. They provide enzymatically synthesized sugar-based molecules used in immunology, vaccine development, and glycobiology research. Their core business lies at the intersection of carbohydrate chemistry and life sciences, supplying specialized reagents and building blocks that academic and pharma partners need for studying how sugars interact with the immune system.

What they specialise in

How they've shifted over time

GlycoUniverse's early H2020 participation (2015–2019) centered on broad carbohydrate immunology — designing sugar molecules that modulate immune responses via lectin receptors (IMMUNOSHAPE) and improving glycoconjugate vaccines (GLYCOVAX). Their most recent project, GLYTUNES (2021–2025), shows a sharper focus on the Siglec-glycan axis and glycomimetics, indicating a move from general carbohydrate immunology toward more targeted immune checkpoint-like mechanisms. This evolution mirrors the wider field's growing interest in Siglec biology as a therapeutic avenue, suggesting GlycoUniverse is tracking frontier science closely.

GlycoUniverse is moving toward immune checkpoint-adjacent glycobiology — expect future work in Siglec-targeted therapeutics and precision immunomodulation using synthetic sugars.

How they like to work

GlycoUniverse consistently joins as a participant, never as coordinator — typical for a specialized SME that contributes materials and expertise rather than managing large consortia. All three projects are MSCA training networks (ITN/ETN), meaning they embed within large academic-industrial consortia to train early-stage researchers. With 28 unique partners across 8 countries from just 3 projects, they integrate well into broad European networks and are likely valued for their niche supply capabilities.

Across 3 projects, GlycoUniverse has collaborated with 28 distinct partners in 8 countries — a wide footprint for a small company, driven by the large consortium sizes typical of MSCA training networks. Their network is pan-European with no single dominant geographic cluster.

What sets them apart

GlycoUniverse occupies a rare niche: a commercial SME that produces complex carbohydrates and glycomimetics for research — most competitors in this space are academic labs, not companies. This makes them a natural industry partner for any consortium needing a commercial supplier of glycan building blocks, enzymatic synthesis capacity, or glycomimetic compounds. For consortium builders, they offer the SME participation box checked plus genuine deep-domain expertise in carbohydrate chemistry.

Highlights from their portfolio

• GLYTUNES
  Most recent and largest-funded project (EUR 252,788), focused on the high-impact Siglec-glycan axis — signals the company's current strategic direction.
• GLYCOVAX
  Directly addressed vaccine design using glycoconjugates — a commercially relevant application area with clear pharma industry demand.
• IMMUNOSHAPE
  First H2020 project, established GlycoUniverse's position in the EU glyco-immunology research community and likely opened doors to subsequent consortia.